MENU
APR 07, 2021 9:00 AM PDT

Keynote Presentation: Doing more with less - Maximizing Phase Appropriate DOE Strategies

Presented at: Bioprocessing 2021
Sponsored by: Roche Diagnostics
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Associate Director, Culture Development Seattle Cell Culture Development, Lundbeck Seattle BioPharmaceuticals, Inc
    BIOGRAPHY

Abstract

One challenge pharmaceutical companies face, is moving promising biotherapeutic products into the clinic as fast as safely possible. Devoting the correct amount of time and resources to early stage products can streamline the late stage and commercial development activities. A cell line change between Phase I/II and Phase III can result in spending significant quality, and regulatory resources to demonstrate comparability between the 1st and 2nd generation products. Early DOE screening studies can select for cell lines that have the most robust manufacturability profile, perhaps negating the need for a cell line switch. As the project progresses, process characterization studies can be very labor intensive and are usually delayed until a product has proven itself worthy of investment through success in early clinical trials. Definitive Screening Designs1  have potential to be a one-stop shop for screening important parameters and optimizing settings with low resource costs. Advanced machine learning methods have revolutionized the analysis of large data sets where the data can be divided into portions for training, testing and validation. During bioprocessing development, the datasets are usually small and until now have not been suitable for portioning the data into different training and validation sets. The fractionally weighted bootstrapping method2 uses the same data set for training and validation.  This auto-validation technique has been employed to successfully de-risk model testing experiments that complete the DOE lifecycle.

1  Jones, Bradley and Nachtsheim, Christopher 2011 Definitive Screening Designs with Added Two-Level Categorical Factors  ASQ.org Vol. 45, No. 2, April 2013

2   Ramsey, Phil and Gotwalt, Chris 2017  Model Validation Strategies for Designed Experiments [Power point Slides] Fall Technical Conference https://falltechnicalconference.org/wp-content/uploads/2018_Presentations/3B-FTC-Ramsey-Final.pdf

Learning Objectives:

1. Identify phase appropriate DOE strategies to minimize development timelines and maximize product life-cycle efficiency

2. Recognize the importance of system variability on the DOE settings and levels explored

3. Understand how to use auto-validation to identify model terms


Show Resources
You May Also Like
JUN 21, 2022 6:00 AM PDT
JUN 21, 2022 6:00 AM PDT
Date: June 21, 2022 Time: 6:00am (PDT), 9:00am (EDT), 3:00pm (CEST) The global understanding and practice of medicine is currently undergoing a revolutionary change. This shift to precision...
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
SEP 13, 2022 8:00 AM PDT
SEP 13, 2022 8:00 AM PDT
Date: September 13, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Preparedness against pandemic diseases demands rapid-response vaccine technology and ready-to-use analytical methods...
JUN 01, 2022 9:00 AM PDT
JUN 01, 2022 9:00 AM PDT
Date: June 01, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 6:00pm (CEST) The manufacturing process for cell and gene therapies is complex and can contain process-related impurities from multiple...
JUN 28, 2022 7:00 AM PDT
JUN 28, 2022 7:00 AM PDT
Date: June 28, 2022 Time: 3:00pm (BST), 4:00pm (CET), 9:00am (CST), 7am (PST) Light-sheet microscopy is an extremely versatile imaging technique with a vast range of implementations that are...
AUG 16, 2022 11:00 AM PDT
AUG 16, 2022 11:00 AM PDT
Date: August 16, 2022 Time: 11:00am (PDT), 2:00pm (EDT), 8:00pm (CEST) Understanding genomic variation in the context of cancer is paramount to identifying disease drivers and informing pers...
Loading Comments...
Show Resources